26 August 2021
The added value and simplicity of data management: the how, the why and what sound data management can bring to your lab
Making it transparent, reproducible, re-usable – the benefits of good data management are manifold. In Monique den Boer’s lab at the Princess Máxima Center for pediatric oncology, the structured practices of data management are now part of the lab’s culture. This has brought not only a wealth of data that everyone can use, but also various international collaborations and publications. We spoke to Judith Boer, long-time data steward within the lab, about the easy but efficient structure she devised and implemented, and the challenges and long-term benefits of storing data well.
9 August 2021
New research reveals that the actionable metastatic cancer genome is remarkably stable
A one-time analysis of the entire tumor DNA is almost always sufficient to find all DNA errors that may be relevant for treating metastatic cancer. This is because actionable DNA errors remain remarkably stable over time, despite treatment with drugs. This discovery was made by Oncode Investigator Emile Voest (NKI) and his team at the Netherlands Cancer Institute, with the financial support of Oncode Institute. Their findings are now published in Nature Medicine.
5 August 2021
Absence of stem cells in pancreas changes view on pancreatic cancer
New research by Oncode Investigator Louis Vermeulen and co-investigator Maarten Bijlsma shows that there are no stem cells in the pancreas. These unexpected findings potentially have major implications for pancreatic cancer research, since stem cells are often at the root of tumor development. This research was published today in the leading journal Cell Stem Cell.
27 July 2021
Antibodies with a mission: what the Utrecht Monoclonal Antibody Facility (UMab) can do for you
As part of the Infrastructure and Technology programme, Oncode started a collaborative project together with Oncode Investigator Linde Meyaard (UMCU) and Jeanette Leusen (head of the Utrecht Monoclonal Antibody Facility (UMab)) with the goal of being able to offer Oncode Investigators the opportunity to produce high quality antibodies (targeted against membrane proteins). Oncode is now looking to fund a total of 4 Oncode Investigators to develop monoclonal antibodies potentially suited for clinical applications in oncology, directed against their membrane target of choice.
20 July 2021
Oncode collaboration results in a new mathematical method that can predict cancer survival based on genetic changes
As cancer survival rates vary widely, Oncode Researcher Daniel Miedema from Oncode Investigator Louis Vermeulen’s lab (Amsterdam UMC), in collaboration with the teams of Oncode Investigators Hugo Snippert (UMC Utrecht) and Geert Kops (Hubrecht Institute) has developed a mathematical method to predict survival based on genetic changes in cancer. The results of this study are now published in Nature Communications.
14 July 2021
Oncode Investigators Hugo Snippert and Jarno Drost receive NWO-Vidi grant
Just announced: The Dutch Research Council has awarded Oncode Investigators Hugo Snippert (UMCU) and Jarno Drost (Princess Máxima Center for pediatric oncology) a NWO-Vidi grant worth 800.000 Euros. The Vidi grant is part of the NWO Talent Programme and will enable them to develop their own innovative line of research in the coming five years.
12 July 2021
Oncode and NKI spinout a new company targeting senescence in oncology, led by Rene Bernards
Over the last 5 years Oncode Investigator Rene Bernards’ laboratory at the NKI has been focused on understanding senescence and its role in tumour biology. This has now culminated in a new company that will take the next step – discover and develop therapeutics that exploit senescence to target tumours.
1 July 2021
Unraveling the genetic evolution of individual tumor cells
The research group of Hugo Snippert reports the first detailed insights into the pace and patterns by which genetic alterations are generated by tumors. The results appear today in the leading journal Nature Genetics and shed new light on the origin of colon tumors.
30 June 2021
Oncode Investigator Jarno Drost and his team part of joint research that uncovers the cellular signatures of kidney tumors
Oncode Investigator Jarno Drost and his team at the Princess Maxima Centre in collaboration with researchers at the Wellcome Sanger Institute and Great Ormond Street Hospital (GOSH) have uncovered the origins of seven types of kidney cancer including several rare subtypes. Their findings confirm that these cancers have their origin in specific forms of developmental cells present in the maturing fetus. The study has recently been published in Nature Communications.
29 June 2021
Fully online, always together: looking back at the third edition of Oncode’s CGC Annual Scientific Meeting
As preparations were in progress for our third Oncode CGC Annual Scientific Meeting, the COVID-19 governmental restrictions kept changing. We had to take some decisions in this shifting environment and the best option was to broadcast the event from a studio and have everything fully online. And even though we did not get a chance to see each other in real life, this year’s edition had a unique flavour of its own. We look back at a successful and interesting event, packed with science and online networking.
22 June 2021
Research/Industry collaboration on potential anti-cancer treatment published in eLife
Oncode Investigator Linde Meyaard, UMC Utrecht, identified the inhibitory immune receptor LAIR-1 and has been working on it for over 20 years. Biotech company NextCure (USA) developed NC410, a product candidate based on the LAIR family of molecules, and reached out to Linde to collaborate. Their joint paper Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction is now published in eLife.
Scroll for more